ReviewEuropean respiratory review : an official journal of the European Respiratory Society2019
Management of pulmonary toxicity associated with immune checkpoint inhibitors.
Review in European respiratory review : an official journal of the European Respiratory Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 100 citations in OpenAlex.
- Efficacy and safety of Nivolumab in advanced gastric and gastroesophageal junction cancer: a meta-analysis of randomized controlled trials.BMC gastroenterology · 2024Pooled it
- Risk of Pneumonitis Associated With Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Network Meta-Analysis.Frontiers in oncology · 2021Pooled it
- The immune-related symptom web in immune checkpoint inhibitor therapy: a longitudinal clinical safety surveillance framework for immune-related adverse events.Frontiers in pharmacology · 2026Review
- Radiation-induced lung injury in the era of combination anticancer therapy: a narrative review.Frontiers in immunology · 2026Review
- Drug-Induced Interstitial Lung Disease in Lung Cancer Patients.Respiration; international review of thoracic diseases · 2026Review
- [Pulmonary complications of immunotherapy, their recognition and treatment].Magyar onkologia · 2025Review
- The predictive role of PNI and NRS2002 for postoperative pulmonary complications in ESCC patients undergoing neoadjuvant chemoimmunotherapy followed by McKeown esophagectomy: a retrospective cohort study.World journal of surgical oncology · 2025Article
- Life-threatening immune-related adverse events in the intensive care unit: a narrative review.Intensive care medicine · 2025Review
- Review
- A real-world cohort study of immune-related adverse events in patients receiving immune checkpoint inhibitors.NPJ precision oncology · 2025Article
- Utility of bronchoalveolar lavage in checkpoint inhibitor pneumonitis evaluation: a narrative review.Translational lung cancer research · 2025Review
- Lung Toxicity from Immune Checkpoint Inhibitors: A Diagnostic Approach.Journal of clinical medicine · 2025Review
- The Current State of Tumor Microenvironment-Specific Therapies for Non-Small Cell Lung Cancer.Cancers · 2025Review
- Palliative care in lung cancer: tumour- and treatment-related complications in lung cancer and their management.Breathe (Sheffield, England) · 2024Review
- Immune checkpoint inhibitor therapy‑related pneumonitis: How, when and why to diagnose and manage (Review).Experimental and therapeutic medicine · 2024Review
- Subjective symptoms are triggers for the detection of immune checkpoint inhibitor-induced interstitial lung disease and associate with disease severity: a single-center retrospective study.Journal of pharmaceutical health care and sciences · 2024Article
- Biomarkers associated with immune-related adverse events induced by immune checkpoint inhibitors.World journal of clinical oncology · 2024Review
- Exploratory mass cytometry analysis reveals immunophenotypes of cancer treatment-related pneumonitis.eLife · 2024Article
- Nivolumab Safety in Renal Cell Carcinoma: A Case Report.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2024Article
- Mediator complex subunit 1 architects a tumorigenic Treg cell program independent of inflammation.Cell reports. Medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy has become a standard of care in oncology, following the recent approvals of cytotoxic T-lymphocyte-associated protein-4 and programmed cell death-1 inhibitors in lung cancer, melanoma, renal cell carcinoma, Hodgkin's lymphoma, bladder, head and neck cancers. Besides their efficacy, these agents also generate specific immune-related adverse events. Due to the increasing prescription of immune-checkpoint inhibitors, the incidence of immune toxicity will continue to rise. The awareness of immune-related adverse events is key to ensuring both diagnosis and management of the possible serious adverse events. Although severe immune-related adverse events remain rare, they can lead to discontinued treatment or to death if they are not forecasted and managed properly. Even if lung toxicity is not the most frequent adverse event, it remains critical as it can be life-threatening. Herein, the main aspects of pulmonary toxicity are reviewed and guidelines are also proposed in order to manage the possible side-effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.